Novo Nordisk A/S reported a 23% increase in sales to DKK 204.7 billion for the first nine months of 2024, driven by a 31% rise in North America, particularly in diabetes and obesity treatments, while operating profit grew by 21% to DKK 91.6 billion. This filing reflects the company’s continued strong performance and investment in R&D, reinforcing its market leadership.